×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CTLT – catalent, inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CTLT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
06:14 am
ctlt
FDA (Food and Drug Administration) Drug Approval Process Training Course: Comprehensive Programme Covering Procedures for Submission of INDs, NDAs, ANDAs and 505(b)(2) (LIVE ONLINE EVENT/ON-DEMAND) [Yahoo! Finance]
Low
Report
FDA (Food and Drug Administration) Drug Approval Process Training Course: Comprehensive Programme Covering Procedures for Submission of INDs, NDAs, ANDAs and 505(b)(2) (LIVE ONLINE EVENT/ON-DEMAND) [Yahoo! Finance]
11/20
07:07 am
ctlt
Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery [Yahoo! Finance]
Low
Report
Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery [Yahoo! Finance]
11/18
08:00 am
ctlt
Matica Biotechnology Appoints Life Sciences Leader Min Park, MBA to Chief Commercial Officer [Yahoo! Finance]
Low
Report
Matica Biotechnology Appoints Life Sciences Leader Min Park, MBA to Chief Commercial Officer [Yahoo! Finance]
11/18
07:12 am
ctlt
Pharmaceutical Outsourcing Launches New Clinical Trials Documentary: Transforming Drug Development: Accelerating Clinical Trials through Patient-Centric Innovations and Technological Breakthroughs [Yahoo! Finance]
Low
Report
Pharmaceutical Outsourcing Launches New Clinical Trials Documentary: Transforming Drug Development: Accelerating Clinical Trials through Patient-Centric Innovations and Technological Breakthroughs [Yahoo! Finance]
11/15
09:09 am
ctlt
OpenText World 2024 Unites Industry Leaders to Tackle AI and Information Management [Yahoo! Finance]
Low
Report
OpenText World 2024 Unites Industry Leaders to Tackle AI and Information Management [Yahoo! Finance]
11/14
05:13 am
ctlt
High Potency API Contract Manufacturing Market Forecast, 2025-2030 - Rising Demand for Oncology Drugs and Advancements in Manufacturing Technology Driving the Industry at 10.98% CAGR [Yahoo! Finance]
Low
Report
High Potency API Contract Manufacturing Market Forecast, 2025-2030 - Rising Demand for Oncology Drugs and Advancements in Manufacturing Technology Driving the Industry at 10.98% CAGR [Yahoo! Finance]
11/14
03:11 am
ctlt
Catalent, Inc. (NYSE: CTLT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Catalent, Inc. (NYSE: CTLT) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/13
12:45 pm
ctlt
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 billion deal [Yahoo! Finance]
Low
Report
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 billion deal [Yahoo! Finance]
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
04:35 pm
ctlt
Form SC 13G/A Catalent, Inc. Filed by: NOMURA HOLDINGS INC
Low
Report
Form SC 13G/A Catalent, Inc. Filed by: NOMURA HOLDINGS INC
11/14
02:46 pm
ctlt
Form 4 Catalent, Inc. For: Nov 11 Filed by: Ryan Michelle R
Low
Report
Form 4 Catalent, Inc. For: Nov 11 Filed by: Ryan Michelle R
11/14
09:50 am
ctlt
Form SC 13G/A Catalent, Inc. Filed by: JANUS HENDERSON GROUP PLC
Low
Report
Form SC 13G/A Catalent, Inc. Filed by: JANUS HENDERSON GROUP PLC
11/13
12:53 pm
ctlt
Form SC 13G/A Catalent, Inc. Filed by: Capital World Investors
Low
Report
Form SC 13G/A Catalent, Inc. Filed by: Capital World Investors
11/12
11:21 am
ctlt
Form 144 Catalent, Inc. Filed by: Ryan Michelle R
Low
Report
Form 144 Catalent, Inc. Filed by: Ryan Michelle R
11/5
04:02 pm
ctlt
Form 10-Q Catalent, Inc. For: Sep 30
Low
Report
Form 10-Q Catalent, Inc. For: Sep 30
11/5
07:11 am
ctlt
Form 8-K Catalent, Inc. For: Nov 05
Low
Report
Form 8-K Catalent, Inc. For: Nov 05
11/1
05:24 pm
ctlt
Form 4 Catalent, Inc. For: Oct 30 Filed by: Barg Steven
Low
Report
Form 4 Catalent, Inc. For: Oct 30 Filed by: Barg Steven
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
Catalent Partners with Biohaven on New Fast-Dissolve Migraine Treatment
10.2%
4/29 Catalent Signs Agreement with Johnson & Johnson to be U.S. Manufacturing Partner for Lead COVID-19 Vaccine Candidate 9.5%
3/9 Catalent, Inc. to Present at the Barclays Global Healthcare Conference 7.8%
6/21 Catalent Inc (NYSE: CTLT) was upgraded by analysts at Jefferies Financial Group Inc from a "hold" rating to a "buy" rating. 5.9%
12/17 Catalent to Host Workshop to Discuss Accelerating Early Drug Development through Consultant Collaboration 4.9%
12/18 Catalent Inc (NYSE: CTLT) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 4.2%
3/3 Form 8-K Catalent, Inc. For: Mar 02 3.9%
4/13 Catalent Publishes Fiscal 2019 Corporate Responsibility Report 3.6%
3/2 Catalent Inc (NYSE: CTLT) is now covered by analysts at Deutsche Bank AG. They set a "hold" rating and a $59.00 price target on the stock. 3.5%
1/13 Age-Appropriate Formulation Development for Pediatric Trials: Challenges and Considerations, Upcoming Webinar Hosted by Xtalks 3.1%
4/29 Catalent Signs Agreement with Johnson & Johnson to be U.S. Manufacturing Partner for Lead COVID-19 Vaccine Candidate 9.5%
3/9 Catalent, Inc. to Present at the Barclays Global Healthcare Conference 7.8%
6/21 Catalent Inc (NYSE: CTLT) was upgraded by analysts at Jefferies Financial Group Inc from a "hold" rating to a "buy" rating. 5.9%
12/17 Catalent to Host Workshop to Discuss Accelerating Early Drug Development through Consultant Collaboration 4.9%
12/18 Catalent Inc (NYSE: CTLT) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 4.2%
3/3 Form 8-K Catalent, Inc. For: Mar 02 3.9%
4/13 Catalent Publishes Fiscal 2019 Corporate Responsibility Report 3.6%
3/2 Catalent Inc (NYSE: CTLT) is now covered by analysts at Deutsche Bank AG. They set a "hold" rating and a $59.00 price target on the stock. 3.5%
1/13 Age-Appropriate Formulation Development for Pediatric Trials: Challenges and Considerations, Upcoming Webinar Hosted by Xtalks 3.1%
TOP News Decliners
3/17
Vectura Group PLC (VEGPF) CEO Will Downie on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha]
-13.9%
8/27 Catalent Earnings Unexpectedly Rise [Investor's Business Daily] -5.4%
2/27 Catalent Announces Supplying Blueprint Medicines' Precision Therapy AYVAKIT™ (avapritinib) -4.8%
4/30 Form 8-K Catalent, Inc. For: Apr 30 -4.2%
5/7 Q3/2019 3/31/2019 EPS 0.220 ZacksConsensus 0.420 ActVsEst (0.200) - Miss -3.9%
2/24 Catalent's Senior Vice President & Chief Financial Officer, Wetteny Joseph, Inducted as a Member of the Executive Leadership Council -3.6%
2/3 Catalent, Inc. Announces Public Offering of Common Stock -3.5%
2/20 Catalent to Host Workshop Demonstrating Advantages of Integrated Biologics Development Solutions in London, U.K. -3.1%
3/27 Catalent Inc (NYSE: CTLT) had its price target lowered by analysts at Morgan Stanley from $67.00 to $57.00. They now have an "overweight" rating on the stock. -3.0%
4/20 Catalent Inc (NYSE: CTLT) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating on the stock. -2.9%
8/27 Catalent Earnings Unexpectedly Rise [Investor's Business Daily] -5.4%
2/27 Catalent Announces Supplying Blueprint Medicines' Precision Therapy AYVAKIT™ (avapritinib) -4.8%
4/30 Form 8-K Catalent, Inc. For: Apr 30 -4.2%
5/7 Q3/2019 3/31/2019 EPS 0.220 ZacksConsensus 0.420 ActVsEst (0.200) - Miss -3.9%
2/24 Catalent's Senior Vice President & Chief Financial Officer, Wetteny Joseph, Inducted as a Member of the Executive Leadership Council -3.6%
2/3 Catalent, Inc. Announces Public Offering of Common Stock -3.5%
2/20 Catalent to Host Workshop Demonstrating Advantages of Integrated Biologics Development Solutions in London, U.K. -3.1%
3/27 Catalent Inc (NYSE: CTLT) had its price target lowered by analysts at Morgan Stanley from $67.00 to $57.00. They now have an "overweight" rating on the stock. -3.0%
4/20 Catalent Inc (NYSE: CTLT) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating on the stock. -2.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: